Histogen Inc
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its prec… Read more
Histogen Inc (HSTO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: -0.611x
Based on the latest financial reports, Histogen Inc (HSTO) has a cash flow conversion efficiency ratio of -0.611x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.69 Million) by net assets ($4.40 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Histogen Inc - Cash Flow Conversion Efficiency Trend (2013–2022)
This chart illustrates how Histogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Histogen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Histogen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SAPPORO HOLDINGS
MU:SBW
|
0.046x |
|
Marr SpA
BE:M6Z
|
0.204x |
|
Active Energy Group PLC
PINK:ATGVF
|
6.473x |
|
AMCJX
NMFQS:AMCJX
|
N/A |
|
Chesnara
LSE:CSN
|
1.212x |
|
Homebiogas Ltd
TA:HMGS
|
-0.172x |
|
Bytes Technology Ltd
LSE:BYIT
|
0.132x |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
0.014x |
Annual Cash Flow Conversion Efficiency for Histogen Inc (2013–2022)
The table below shows the annual cash flow conversion efficiency of Histogen Inc from 2013 to 2022.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | $13.38 Million | $-9.68 Million | -0.724x | -0.56% |
| 2021-12-31 | $20.19 Million | $-14.53 Million | -0.720x | +58.71% |
| 2020-12-31 | $6.91 Million | $-12.05 Million | -1.744x | -5228.10% |
| 2019-12-31 | $-37.97 Million | $-1.29 Million | 0.034x | +102.67% |
| 2018-12-31 | $27.40 Million | $-34.86 Million | -1.272x | -7.25% |
| 2017-12-31 | $28.00 Million | $-33.21 Million | -1.186x | -195.74% |
| 2016-12-31 | $21.79 Million | $27.00 Million | 1.239x | +289.82% |
| 2015-12-31 | $34.54 Million | $-22.55 Million | -0.653x | -18.73% |
| 2014-12-31 | $33.21 Million | $-18.26 Million | -0.550x | -174.68% |
| 2013-12-31 | $53.12 Million | $-10.63 Million | -0.200x | -- |